Abstract：Objective To study the common etiology and infection characteristics of community-acquired pneumonia in elderly patients in emergency department. Methods A total of 79 elderly patients who were diagnosed with community-acquired pneumonia in the emergency department of Beijing Jingmei Group General Hospital from March 2020 to October 2021 were retrospectively analyzed. Qualified sputum samples were taken, common etiology was analyzed, the clinical characteristics of patients with mixed infection and single bacterial infection were compared. The variables with statistically significant difference in univariate analysis were included in logistic multivariate regression analysis. Results The detection rate of Gram-negative bacilli such as Klebsiella pneumoniae and Pseudomonas aeruginosa were higher in elderly patients with community-acquired pneumonia. Acinetobacter baumannii has a high drug resistance rate. The results of univariate analysis showed that mixed infection was related to dependence on gastric tube, urinary tube, bedridden status, history of antibiotic abuse, respiratory disease, type 2 diabetes, and infection rate of multi-drug resistant bacteria, and the differences were statistically significant (P<0.05). Multivariate analysis results of logistic regression model showed that type 2 diabetes (β=2.166, OR=8.723, 95%CI=2.195-34.671), multi-drug resistant bacteria infection (β=1.749, OR=5.746, 95%CI=1.166-28.323) were independent risk factors for mixed infection (P<0.05). Conclusion The bacteria isolated from community-acquired pneumonia in elderly patients gradually appear to have a bacterial spectrum similar to that of hospital-acquired pneumonia bacteria. Type 2 diabetes and multi-drug resistant bacteria infection are independent risk factors for mixed infection.
Luna CM，Palma I，Niederman MS，et al.The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia[J].Ann Am Thorac Soc，2016，13（9）：1519-1526.
Cillóniz C，Dominedò C，Pericàs JM，et al.Community-acquired pneumonia in critically ill very old patients：a growing problem[J].Eur Respir Rev，2020，29（155）：190126.
[3]
Kang SH，Jo YH，Lee JH，et al.Antibiotic prescription consistent with guidelines in emergency department is associated with 30-day survival in severe community-acquired pneumonia[J].BMC Emerg Med，2021，21（1）：108.
[4]
Cao B，Huang Y，She DY，et al.Diagnosis and treatment of community-acquired pneumonia in adults：2016 clinical practice guidelines by the Chinese Thoracic Society，Chinese Medical Association[J].Clin Respir J，2018，12（4）：1320-1360.
[9]
Metlay JP，Waterer GW，Long AC，et al.Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America[J].Am J Respir Crit Care Med，2019，200（7）：e45-e67.
[10]
Vardakas KZ，Rafailidis PI，Konstantelias AA，et al.Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study，the patient，the bug or the drug?[J].J Infect，2013，66（5）：401-414.
[11]
Martin-Loeches I，Torres A.New guidelines for severe community -acquired pneumonia[J].Curr Opin Pulm Med，2021， 27（3）：210-215.
[12]
Song JH，Huh K，Chung DR.Community-Acquired Pneumonia in the Asia-Pacific Region[J].Semin Respir Crit Care Med，2016，37（6）：839-854.
[13]
Rastogi R，Yu PC，Deshpande A，et al.Treatment and outcomes among patients ≥85 years hospitalized with community-acquired pneumonia[J].J Investig Med，2022，70（2）：376-382.
[14]
Dunn SJ，Connor C，McNally A.The evolution and transmission of multi-drug resistant Escherichia coli and Klebsiella pneumoniae: the complexity of clones and plasmids[J].Curr Opin Microbiol，2019，51：51-56.
[15]
Kumagai S，Ishida T，Tachibana H，et al.Polybacterial aetiology and outcomes in patients with community-acquired pneumonia[J].Int J Tuberc Lung Dis，2016，20（1）：129-135.
[16]
Perez AC，Pang B，King LB，et al.Residence of Streptococcus pneumoniae and Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and bacterial persistence in vivo[J].Pathog Dis，70（3）：280-288.
[17]
Montravers P，Harpan A，Guivarch E.Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia[J].Adv Ther，2016，33（2）：151-166.
京公网安备 11010502046607号